Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.47 |
| ▸ | TNF | P01375 | 2/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.45 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | IL1B | P01584 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22692211 | 0.83 | CRBN (0.45) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL20852258 | 0.81 | CRBN (0.48) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL23292818 | 0.77 | CRBN (0.65) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL23895828 | 0.75 | CRBN (0.41) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL24822426 | 0.74 | CRBN (0.43) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL23696007 | 0.74 | CRBN (0.56) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL19503624 | 0.74 | CRBN (0.50) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL10023168 | 0.73 | CRBN (0.59) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL22737559 | 0.73 | CRBN (0.49) | CRBNTNFDDB1IKZF3ALDH1A1 | |
| SCHEMBL25698653 | 0.72 | CRBN (0.50) | CRBNTNFDDB1IKZF3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885TNF 4636/4885DDB1 750/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | CRBN 3/4885TNF 4636/4885DDB1 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.